Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of polysaccharide antigenic components. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galFcontaining antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing Intelectin-1 binding to galFcontaining antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to Streptococcus pneumoniae, Klebsiella pneumonia, Escherichia coli, Mycobacteria species, Malassezia species, Aspergillus species, Fusarium species, Alternaria species, Coccidioides species, Cryptococcus species, Mucormycetes, Histoplasma species, Neosartorya species, Fusarium species, Paracoccidioides species, or combinations thereof.

The present invention provides a sandwich assay for quantifying a glycoprotein, which is a substance to be detected, in a sample using a labeled lectin, wherein the effect attributed to a contaminant, namely noise on the quantified value of the substance to be detected, is suppressed by introduction of a simple treatment. The sandwich assay includes a treatment for inhibiting the binding of the labeled lectin to a sugar chain carried by the contaminant non-specifically adsorbed to the measurement region, which contaminant is contained in the sample and which sugar chain is the same as that of the substance to be detected.

Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 23-cGAMP, 22-cGAMP, 32-cGAMP and 33-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.

This application features a method of forming a nanoporous layer. The method includes steps of reducing metal ions in a reverse micelle phase composition to form nanoparticles, removing surfactant from the composition to form clusters of the nanoparticles, dispensing the composition including the nanoparticle clusters dispersed in a liquid on a substrate, and drying to form the nanoporous layer. The nanoporous layer includes nanoparticles deposited to form a three dimensional network of irregularly shaped bodies. The nanoporous layer also includes a three dimensional network of intercluster spaces that are not occupied by the three dimensional network of irregularly shaped bodies.

The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.

Provided are methods and related kits for detection of early stage pancreatic ductal adenocarcinoma. Also provided are methods for treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.

Provided herein are methods of diagnosing or monitoring the treatment of mucopolysaccharidosis (MPS) I or a disorder associated with MPS I.

Reagents comprising MS active, fluorescent molecules with an activated functionality for reaction with amines useful in tagging biomolecules such as N-glycans and uses thereof are taught and described.

The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.

Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 23-cGAMP, 22-cGAMP, 32-cGAMP and 33-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.